Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer

Inclusion Criteria: * Adults over age 18 years of age with a life expectancy of at least 3 months. * Histologically or cytologically confirmed stage IIIB or stage IV non squamous non-small-cell lung cancer (NSCLC) who have progressed after 1 chemotherapy regimen. * Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST, Version 1.1) on cross-sectional imaging that is at least 2 cm in longest diameter. * Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2. * Adequate hematologic, renal, and hepatic function. * PT/INR ≤ 1.5 × ULN; aPTT time ≤ 1.5 × ULN. * New York Heart Association classification I or II Exclusion Criteria: * Squamous, small cell, or mixed histology. * Known history of bleeding diathesis or coagulopathy. * Cavitary tumors or tumors invading or abutting large blood vessels. * Bleeding: Clinically significant bleeding such as gross hematuria, GI bleeding and hemoptysis within 12 months of Screening. * Venous thromboembolic events within 6 months of screening. * Ongoing therapy with oral or parenteral anticoagulants. * Concurrent estrogens, anti-estrogens or progesterone compounds. * Radiotherapy within 2 weeks or major surgery within 4 weeks preceding Study Day 1. * Symptomatic or clinically active brain metastases. * Symptomatic coronary artery disease, cerebrovascular accident, transient ischemic attack, myocardial infarction or unstable angina pectoris within 6 months of screening. * Grade 2 or higher peripheral neuropathy